Inovio Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 05/08/2024
Inovio Pharmaceuticals Stock Forecast and Price Target
Inovio Pharmaceuticals's most recent price target of $14.50 for 2024 was provided by two renowned analysts over the past few months, with an average prediction of $14.50. If this prediction is correct, Inovio Pharmaceuticals's stock could rise by 22.05 percent from its current trading price. The potential increase for the stock is $14.50 per share, with a possible range of $8.00 to $40.00. Even if you are not interested in INO stock, it is still imperative to be aware of its competitors.
22.05% Upside
Inovio Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Inovio Pharmaceuticals's Price has grown from $0.00 to $0.00 – a 100.00% increase. Next year, analysts are expecting Fair Value to reach $12.74 – an increase of 100.00%. Over the next twelve years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$106.17 | Buy/Sell | $118.92 | 19.15% |
| ISRG Stock Forecast | Intuitive Surgical | Outperform |
13
|
$388.65 | Buy/Sell | $408.45 | 10.90% |
| BSX Stock Forecast | Boston Scientific | Buy |
11
|
$73.43 | Buy/Sell | $70.14 | 11.67% |
| DXCM Stock Forecast | DexCom Inc | Buy |
12
|
$130.10 | Buy/Sell | $125.98 | 15.30% |
| RMD Stock Forecast | ResMed Inc | Outperform |
17
|
$216.16 | Buy/Sell | $201.32 | 1.55% |
Inovio Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
Inovio Pharmaceuticals's Revenue has decreased In the last three years, from $7.41M to $830.00k – a 88.80% drop. Next year, analysts are expecting Revenue to reach $2.14M – an increase of 157.83%. Over the next ten years, the forecast is for Revenue to grow by 61628.92%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| VAR Stock Forecast | Varian Medical Systems | - |
16
|
$176.53 | Buy/Sell | $177.67 | -100.00% |
| SWAV Stock Forecast | Shockwave Medical | Hold |
4
|
$330.49 | Buy/Sell | $239.91 | 1.36% |
| PODD Stock Forecast | Insulet | Outperform |
15
|
$184.28 | Buy/Sell | $222.05 | 29.15% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LVGO Stock Forecast | Livongo Health | - |
0
|
$0.00 | Buy/Sell | $126.17 | 0.00% |
| INSP Stock Forecast | Inspire Medical Systems | Outperform |
6
|
$245.63 | Buy/Sell | $225.45 | 7.89% |
| MASI Stock Forecast | Masimo | Outperform |
14
|
$136.00 | Buy/Sell | $96.33 | 17.65% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ITGR Stock Forecast | Integer Holdings | Outperform |
16
|
$113.14 | Buy/Sell | $95.00 | 14.90% |
| AXNX Stock Forecast | Axonics | Hold |
7
|
$67.38 | Buy/Sell | $70.15 | 5.37% |
| CMD Stock Forecast | Cantel Medical LLC | - |
17
|
$0.05 | Buy/Sell | $85.00 | -100.00% |
Inovio Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Inovio Pharmaceuticals's EBITDA has grown, rising from $-120.50M to $-130.66M – a growth of 8.43%. In the next year, analysts believe that EBITDA will reach $-154.65M – an increase of 18.36%. For the next seven years, the forecast is for EBITDA to grow by 63.38%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IRTC Stock Forecast | iRhythm Technologies | Buy |
11
|
$106.22 | Buy/Sell | $126.70 | 27.09% |
| TMDX Stock Forecast | TransMedics Group | Outperform |
8
|
$127.28 | Buy/Sell | $90.00 | -3.76% |
| TNDM Stock Forecast | Tandem Diabetes Care | Outperform |
9
|
$44.00 | Buy/Sell | $30.80 | 4.55% |
Inovio Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
Inovio Pharmaceuticals's EBIT has grown In the last three years, rising from $-124.08M to $-133.43M – a growth of 7.54%. In the following year, 4 experts forecast that Inovio Pharmaceuticals's EBIT will decrease by 20.24%, to $-106.42M. In 2030, professionals predict that Inovio Pharmaceuticals's EBIT will decrease by 373.75%, to $365.26M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CNMD Stock Forecast | CONMED | Outperform |
16
|
$71.65 | Buy/Sell | $123.38 | 20.73% |
| GNMK Stock Forecast | GenMark Diagnostics | - |
2
|
$0.00 | Buy/Sell | $24.05 | 0.00% |
| NTUS Stock Forecast | Natus Medical | - |
14
|
$32.96 | Buy/Sell | $36.00 | 16.60% |
Inovio Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Inovio Pharmaceuticals's EPS has grown from $-0.83 to $0.00 – a 100.00% increase. Next year, analysts are expecting EPS to reach $-0.33 – an increase of 100.00%. Over the next twelve years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SILK Stock Forecast | Silk Road Medical, Inc | Outperform |
7
|
$20.90 | Buy/Sell | $12.33 | 0.48% |
| QTRX Stock Forecast | Quanterix | Outperform |
11
|
$16.80 | Buy/Sell | $32.00 | 90.48% |
| SOLY Stock Forecast | Soliton | - |
4
|
$22.59 | Buy/Sell | $23.00 | -100.00% |
Site Navigation
.jpg)